
Blood Biomarker Signals Alzheimer’s Risk Years Before Symptoms
A multi-cohort study shows baseline blood levels of p-tau217 predict future cognitive impairment in cognitively unimpaired older adults, with a 38% absolute risk at 5 years and 78% at 10 years, independent of amyloid PET or APOE4 status; current guidance cautions against routine use in asymptomatic individuals since no disease-modifying therapies exist, but the test can rapidly identify high-risk candidates for prevention trials and could eventually become a standard screening tool like cholesterol tests.













